BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Verdiva Bio readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Verdiva Bio's drugs run\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07243171-268@assetmemo.bio
DTSTAMP:20261121T005813Z
DTSTART;VALUE=DATE:20270105
DTEND;VALUE=DATE:20270106
SUMMARY:Ecnoglutide (VRB-101): Phase 1/2 readout est. (NCT07243171)
DESCRIPTION:Ecnoglutide (VRB-101)\, phase 1/2\, Obesity.\nStudy: A Phase Ib
 /IIa Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Ph
 armacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Ov
 erweight or Obesity\nEstimated primary completion: 5 January 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ecnoglutide-vrb-101#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07243171
URL:https://assetmemo.bio/drug/ecnoglutide-vrb-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
